Abstract
T-3262, a new pyridone-carboxylic acid derivative, was clinically studied with the following results.
1) T-3262 was administered for 3-15 days at a dose of 150 mg b. i. d. or t. i. d. after meals to a total of 25 patients: 1 with acute otitis media, 4 with chronic otitis media, 5 with acute exacerbation of chronic otitis media, 1 with acute sinusitis, 5 with acute exacerbation of chronic sinusitis, 3 with acute lacunar tonsillitis, 3 with peritonsillar abscess, and 1 with acute otitis externa. Clinical efficacy was assessed as excellent in 7 cases, good in 9, fair in 7 and poor in 2, the clinical efficacy rate being 64.0%.
2) In the bacteriological evaluation, the eradication rate in 19 cases of monomicrobial infection was 92. 9% and that in 5 cases of polymicrobial infection was 75.0%.
3) No adverse events or abnormal laboratory findings were observed.
